Notably, the patient responded rapidly to Anakinra (an IL-1 receptor antagonist), achieving sustained remission, demonstrating the potential role of IL-1 blockade as an early therapeutic option in MAS-SLE [6,11]. Here, IL1B is linked to systemic lupus erythematosus.